X4 Pharmaceuticals, Inc.
NASDAQ:XFOR
Overview | Financials
| Company Name | X4 Pharmaceuticals, Inc. |
| Symbol | XFOR |
| Currency | USD |
| Price | 3.39 |
| Market Cap | 38,674,137 |
| Dividend Yield | 0% |
| 52-week-range | 1.35 - 26.82 |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Dr. Paula Ragan Ph.D. |
| Website | https://www.x4pharma.com |
An error occurred while fetching data.
About X4 Pharmaceuticals, Inc.
X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD





